Search This Blog

Saturday, December 4, 2021

Early tests suggest Vir, Glaxo antibody could hold up versus omicron

 

  • Vir Biotechnology and GlaxoSmithKline's antibody drug for COVID-19 might retain some of its potency against the omicron variant, the companies said Thursday, citing laboratory tests involving engineered viruses containing some of the same mutations that are present in omicron.
  • Those tests only matched up Vir and GSK's drug against individual mutations found in omicron, rather than the complete array of genetic changes that have fueled global concern over the potential for the new coronavirus variant to evade current drugs and vaccines.
  • Laboratory research with a "pseudo-virus" mimicking omicron as a whole is ongoing, VIR and GSK said, and will give a better sense of whether their antibody drug could still retain its effectiveness in preventing hospitalization and death from COVID-19.

Omicron's detection last week triggered travel restrictions and renewed public health measures around the world as scientists and government officials warned the variant may more readily spread and cause disease.

But many of the most important questions, such as whether infection from the variant causes more severe symptoms or whether it can sidestep vaccine protection, remain unanswered. Data should be available within the next week or two, as researchers study the variant in greater detail and more cases accumulate.

For vaccine and drug developers, omicron's threat will initially be measured by lab tests that analyze whether their treatments can still neutralize the variant. Scientists commonly use genetic data to engineer pseudo-viruses that replicate the real thing, rather than use live virus samples. Those pseudo-viruses are then mixed with blood from vaccinated individuals or, in the case of antibody drugs, the medicines themselves.

The data released by Vir and GSK are an early attempt at this, using already available pseudoviruses that contain some of the same key mutations as found in omicron. For all individual mutations the companies pitted their drug against, they found it retained neutralizing activity. Psuedo-type viruses containing some of omicron's more concerning mutations, however, weren't available.

The effect of omicron's mutations in sum may also be different than each of those mutations individually, meaning Vir and GSK's data can only be counted on so much to predict whether their drug will be equally effective against omicron as the original coronavirus strain. The drug retained potency against prior variants, including delta.

"We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of omicron," said Vir CEO George Scangos in a statement.

Vir and GSK's drug, called sotrovimab, is available in the U.S. under an emergency authorization granted by the Food and Drug Administration in May. The companies designed it to bind to a region of the coronavirus' spike protein that they claim is "conserved" even as the virus mutates.

While Vir and GSK are confident their antibody will work versus omicron, other antibody drug developers aren't as certain. Regeneron, for example, warned this week that its cocktail of two antibodies may not be effective against the variant, although tests are ongoing.

Vaccine makers, too, are concerned that omicron may escape the immune protection their shots generate and are already readying omicron-specific versions in preparation.

https://www.biopharmadive.com/news/vir-gsk-omicron-variant-antibody-potency/610857/

How Omicron Variant Got So Many Mutations So Quickly

 On November 25, South African scientists announced the discovery of a new, “heavily mutated” variant of the coronavirus, triggering global panic. Countries quickly imposed travel bans and closed their borders, but the variant has already been detected in at least 23 countries, including the U.S.

One reason for the knee-jerk reactions is the new variant’s high number of mutations: Omicron, as it has been dubbed by the World Health Organization, has more than 30 changes to its spike protein. This protein allows the virus to infect and take over human cells, and is also the target of most vaccines. Spike protein changes in previous variants, such as Delta and Alpha, are thought to have made the virus more infectious or more likely to evade the immune system and vaccines. It is not yet clear whether Omicron is more transmissible, or causes more severe disease than previous variants, or whether it will render the vaccines less effective. But a new pre-print study released by South African scientists on Thursday, which has been not yet been published in a scientific journal, suggests that Omicron is three times more likely to reinfect people.

Mutations develop spontaneously as a virus replicates and spreads, but scientists are now trying to understand how so many mutations arose in Omicron in such a seemingly short space of time.

“The question is how this [rapid evolution] occurred, where it occurred, and which were the conditions that fueled [it],” says Gonzalo Bello, a virologist at the Oswaldo Cruz Institute in Rio de Janeiro. Bello was part of the team that tracked the rise of the Gamma variant in Brazil in November 2020, which fueled outbreaks in that country. With Gamma, “we realized that mutations did not appear in a single step in a single individual,” Bello explains. Instead, some mutations occurred in certain individuals but not in others. The rise of Gamma “was a process that occurred in a population of individuals, not in a single [person],” he says.

One possibility for how a heavily mutated variant, such as Omicron, could have arisen is that the virus began circulating and mutating in an isolated group of people, where it would have had an opportunity to change dramatically compared with variants outside of that bubble. It could then have gotten introduced, with its numerous mutations, into the larger population, where it was able to travel into different groups and countries, Bello says.

Alternatively, the virus may have mutated significantly in a single individual before finding a new host. “This could happen in an immune-suppressed person,” such as someone with HIV, Anna-Lise Williamson, chair in vaccinology at the University of Cape Town, and Ed Rybicki, director of the university’s biopharming research unit, wrote in response to e-mailed questions. South Africa has the world’s largest HIV epidemic, with more than seven million people infected with the virus. Neighboring countries also have widespread HIV infections. This has led some scientists to hypothesize that Omicron arose in Southern Africa because it was first identified there, but older cases have since been identified in European countries and the U.S.

Healthy people have many immune cells called CD4+ T cells, which stimulate another type called killer T cells, Williamson and Rybicki explain. In healthy people who get COVID, these killer T cells destroy the virus-infected cells. But in immunocompromised people, who have low numbers of CD4+ T cells, “the virus establishes a persistent infection” because of a lack of killer-T-cell responses. Their immune systems do, however, produce some immune cells called B cells that trigger an antibody response, and this “results in an arms race between the virus and antibodies,” according to Williamson and Rybicki. The weak B-cell response does not create enough antibodies to clear the virus completely, and consequently the genetic sequence for the virus’s spike protein undergoes pressure to mutate to escape the antibodies.

There is some evidence to support this idea. In a preprint study released in June, South African researchers described an HIV-positive woman who had a SARS-CoV-2 infection for more than six months. During that time, the virus in her evolved and developed a number of mutations, some of them on the spike protein.

Another possible hypothesis for how the virus rapidly gained so many mutations is that it spilled back into an animal reservoir before reinfecting humans, Bello says. Persuasive evidence suggests that the original SARS-CoV-2 likely arose in a bat, and there have been numerous cases of other wild and domesticated mammals contracting the virus. Last year, there were reports of coronavirus outbreaks on mink farms in North America and Europe, and in the Netherlands there was a confirmed case of the mink infecting a farm worker.

Omicron may have jumped from animals to humans in this way, Bello says. “In another species, the virus will face a different kind of immune pressure, and so it could accumulate some mutations quite fast,” he says. The idea is mainly conjecture at this point, however.

To fully understand where Omicron arose, it helps to determine the earliest human patient or community in which it spread. But it is difficult to identify the patient zero for a variant, says Akiko Iwasaki, a professor of immunobiology and molecular, cellular and developmental biology at Yale University. “That is because [virus] surveillance efforts only capture a fraction of infected people,” she says. As more people are tested, and their viral genomes are sequenced, it may be possible to pinpoint a general geographic area and an approximate time when the virus mutated into Omicron, Iwasaki says.

For Michael Head, a senior research fellow in global health at the University of Southampton in the U.K., Omicron is a wake-up call about vaccine inequity and the need for greater access. According to Oxford University’s Our World in Data platform, as of November 30, about eight billion vaccinations had been administered globally, and only 6 percent of people in low-income countries had received at least one dose. African countries have administered more than 235 million vaccines, according to the African Centers for Disease Control and Prevention, but the continent’s population exceeds 1.2 billion people.

“The main variants that have caused concern so far—in terms of Alpha to Delta, basically—have emerged from uncontrolled outbreaks in unvaccinated populations,” Head says. “That’s where COVID thrives best and that’s where the virus has the greater chance to mutate. If [the vaccine] can keep outbreaks under control, you reduce those opportunities.”

The World Health Organization’s Director-General Tedros Adhanom Ghebreyesus echoed these sentiments on November 28: “The Omicron variant reflects the threat of prolonged vaccine injustice,” he wrote in a tweet. “The longer we take to deliver #VaccinEquity, the more we allow the #COVID19 virus to circulate, mutate and become potentially more dangerous.”

https://www.scientificamerican.com/article/how-the-omicron-variant-got-so-many-scary-mutations-so-quickly/

Merck KEYTRUDA OKd as Adjuvant Treatment for Adult and Pediatric Melanoma

 KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC Melanoma

KEYTRUDA Is Now Approved as Adjuvant Treatment for Patients (≥12 Years of Age) With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III Disease

https://finance.yahoo.com/news/fda-approves-merck-keytruda-pembrolizumab-231500886.html

Missouri reports first case of omicron COVID-19 variant in St. Louis City

  Missouri reported its first case of the omicron coronavirus variant on Friday. 

The Missouri Department of Health and Senior Services said a sample presumed positive for the omicron variant from a St. Louis City resident who had recently traveled domestically. The health department is waiting for the CDC to confirm the sample.

The World Health Organization said omicron is a variant of concern due to its mutation capabilities. 

“Although there is much we still need to learn about this new variant, we do know the best tool currently available to protect ourselves from COVID-19 is personal prevention. I urge Missourians to seek information on the Omicron variant from DHSS and trusted medical sources opposed to social media,” Donald Kauerauf said. He's the department's director. “We also encourage Missourians to remain vigilant in protecting themselves and staying informed this holiday season as this new variant is investigated further.”

https://www.kmov.com/news/missouri-reports-first-case-of-omicron-covid-19-variant-in-st-louis-city/article_65473792-547e-11ec-843c-af70ff37dd53.html

Researcher questions China’s population data, says it may be lower

 China may be downplaying how fast its population is shrinking, and a recent policy to promote three-child families has poor chances to improve birth rates, a fertility expert told the Reuters Next conference on Friday.

Fuxian Yi, senior scientist in the obstetrics and gynecology department at the University of Wisconsin, said he estimated that China’s 2020 population was 1.28 billion rather than the 1.41 billion census number reported and that fertility rates were lower than reported.

Yi estimates that China’s population has been shrinking since 2018.

China’s government did not immediately respond to a request for comment.

The country’s rapidly shrinking birth rate has raised concerns of slower economic growth and the potential challenges created by fewer workers supporting an older population.

Beijing scrapped its decades-old one-child policy in 2016, replacing it with a two-child limit to try to stave off those risks. In May a three-child policy was announced as the birth rates continued to drop given the high cost of raising children in Chinese cities.

Author and journalist Lenora Chu said the cost of education in China and the mental stress of exams to climb the education ladder were a challenge. “That’s partly why these family planning policies have to be paired with educational reform policies. Otherwise parents are just going to not want to have more children,” she told the Reuters Next conference.

Chu is the author of the 2017 book about China’s education system “Little Soldiers: An American Boy, a Chinese School, and the Global Race to Achieve.”

China had a fertility rate of just 1.3 children per woman in 2020, recent state data showed, on par with aging societies like Japan and Italy and far short of the roughly 2.1 needed for replacement level.

Yi estimates that the real fertility rate is much lower based on a drop in fertility rates over the years by China’s ethnic minority groups which were not restricted by the one-child policy, and he calculated the population based on his own lower estimate rates.

Yi said local governments overstate their population to obtain more subsidies, including education fees they collect from the central government. He said that with over 20 social benefits linked to a birth registration, some families were using the black market to buy a second birth certificate online.

“The population numbers have been inflated mainly for financial benefits,” Yi said.

https://wsau.com/2021/12/03/researcher-questions-chinas-population-data-says-it-may-be-lower/

FDA adds strict safety warnings to arthritis medications

 The U.S. health regulator added its strictest warning to labels of drugs from Pfizer (PFE.N), Eli Lilly (LLY.N) and AbbVie (ABBV.N) belonging to a class of anti-inflammatory treatments called JAK inhibitors, which cite the risk of serious health issues and death in patients 50 and older, drugmakers said Friday.

The addition of the warning to labels follows Pfizer’s agency review of Xeljanz after initial results from a trial in February showed an increased risk of serious heart -related problems and cancer in some patients who treated with medicine. read more

Xeljanz, which brought in global sales of $ 2.44 billion for Pfizer in 2020, has been approved in the United States for the treatment of conditions including rheumatoid arthritis, psoriatic arthritis and ulcerative colitis – an inflammatory bowel disease.

AbbVie’s Rheumatoid arthritis drugs Rinvoq and Pfizer’s Xeljanz are now recommended for use only in patients, who have had an inadequate response or intolerance to one or more TNF blockers, which is another class of drugs used against in inflammatory conditions.

The Food and Drug Administration’s boxed warnings on the labels of Rinvoq, Xeljanz and Lilly’s Olumiant flag the risk of cardiovascular death and stroke in high-risk patients age 50 and older, and currently or a former smoker.

Additional information about the risk of certain types of cancer and death was also added to their labels.

Marketing applications for the extended use of Rinvoq in atopic dermatitis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis remain under review by the FDA, AbbVie said.

https://newsfounded.com/ethiopia/fda-adds-strict-safety-warnings-to-arthritis-medications-from-pfizer-abbvie-and-lilly/

Pfizer CEO says vaccine data for those under 5 could be available by end of year

 Pfizer's CEO on Friday said data about the effectiveness of its coronavirus vaccine in those under the age of five could be available by the end of the year.

CEO Albert Bourla spoke with NBC News chief White House correspondent Kristen Welker about the new data on Friday.

"We have a study in children six months to two years and then another cohort of children two to five years," Bourla said. "So [by] end of the year, beginning of next year, when we see the data, we will know more."

Pfizer has been at the head of the U.S.'s vaccine campaign as it is currently the only coronavirus vaccine to be approved for everyone above the age of five. 

The announcement of data for those under the age of five comes as the new omicron variant has made its way to at least 10 states.

Scientists are still working to gather data on how effective the coronavirus vaccines will be against the new variant that has more than 30 different mutations. 

Health experts are confident the vaccines will still be the best way to combat the new variant. 

President Biden said the U.S. will not shut down again and will focus on promoting vaccines and booster shots to combat the omicron variant.

https://thehill.com/policy/healthcare/584322-pfizer-ceo-says-vaccine-data-for-those-under-5-could-be-available-by-end-of